查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1468084

2024-2032 年霍乱疫苗市场报告（按疫苗类型、产品、最终用户和地区划分）

Cholera Vaccines Market Report by Vaccine Type, Product, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球霍乱疫苗市场规模达540万美元。公众对霍乱预防的认识不断提高、强有力的政府倡议和国际合作、疫苗技术的不断进步、旅行和贸易的激增、持续的研发活动以及对全球健康的重视是推动市场增长的一些因素。

霍乱疫苗是一种旨在预防霍乱的医疗干预措施，霍乱是一种导致腹泻并可能导致脱水甚至死亡的细菌感染。它们是使用灭活或减毒的霍乱弧菌（霍乱病原体）组合开发的。这个过程涉及培养大量细菌，使它们无毒，然后将它们配製为疫苗。霍乱疫苗的优点是显着的，例如它们提供了预防霍乱爆发的积极方法，特别是在卫生设施和供水不足的地区。透过增强免疫系统识别和对抗霍乱细菌的能力，这些疫苗可以减少疾病的严重程度和持续时间。此外，它们还有助于减少霍乱在社区内和跨国传播。霍乱疫苗的两种主要类型包括口服疫苗和注射疫苗。

全球霍乱疫苗市场受到霍乱预防意识不断增强和疫苗接种重要性的影响，特别是在容易爆发疫情的地区。此外，政府措施和国际组织透过疫苗接种活动控制霍乱传播的努力在市场扩张中发挥关键作用。此外，疫苗技术的进步导致开发出更有效率、更具成本效益的疫苗，从而促进了市场成长。此外，旅行和国际贸易频率的增加促进了对霍乱疫苗接种的需求，因为旅行者可能会跨境携带这种疾病，这反过来又支持了市场的成长。除此之外，旨在提高疫苗功效和安全性的持续研发（R＆D）活动也有助于市场成长。

霍乱疫苗市场趋势/驱动因素：

提高认识与预防霍乱

人们对霍乱预防的认识不断提高以及疫苗接种的关键作用，对全球霍乱疫苗市场产生了重大推动力。随着社区越来越了解霍乱疫情的破坏性影响，对包括疫苗接种在内的有效预防措施的需求也随之增加。这种认知的提高往往是由公共卫生运动、教育倡议和媒体报道推动的，这些运动、教育倡议和媒体报道强调了霍乱的后果以及疫苗接种在遏制其传播方面的重要性。这个驱动因素不仅激发了个人和社区对疫苗接种的兴趣，也鼓励政府、医疗保健组织和国际机构为疫苗接种活动分配资源，推动市场成长。

政府措施和国际努力

政府措施和国际组织的合作努力为全球霍乱疫苗市场的扩张做出了重大贡献。霍乱高发地区政府意识到霍乱造成的社会经济负担，并将疫苗接种计画作为重要的预防策略。此外，世界卫生组织（WHO）和联合国儿童基金会等国际组织与各国政府建立伙伴关係，提供技术专业知识、资金和疫苗供应，以支持疫苗接种活动。这种协调一致的方法不仅确保了资源有限地区的疫苗可及性，而且透过创造对霍乱疫苗的稳定需求，为市场成长创造了有利的环境。

疫苗技术的进步

疫苗技术的进步在推动全球霍乱疫苗市场向前发展方面发挥关键作用。由于研发工作的重点是提高疫苗功效、安全性和生产工艺，更新、更有效的霍乱疫苗被引入市场。这些进步使得疫苗能够提供更持久的保护，需要更少的剂量，并且适合更广泛的年龄层。此外，口服疫苗等疫苗输送机制的创新有助于提高疫苗的接受度和管理的便利性，特别是在医疗基础设施有限的地区。疫苗技术的不断发展不仅提高了霍乱疫苗的整体有效性，还透过为医疗保健提供者和社区提供更好的疾病预防工具来推动市场成长。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球霍乱疫苗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疫苗类型

  • 带有重组 B 亚基的全细胞霍乱弧菌 O1
    • 市场走向
    • 市场预测
  • 杀死口服 O1 和 O139
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依产品

  • 杜科拉尔
    • 市场走向
    • 市场预测
  • 尚科尔
    • 市场走向
    • 市场预测
  • 瓦克斯乔拉
    • 市场走向
    • 市场预测
  • Euvichol 和 Euvichol-Plus
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院和诊所
    • 市场走向
    • 市场预测
  • 研究和学术实验室
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Astellas Pharma Inc.
    • Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
    • Emergent BioSolutions Inc.
    • Eubiologics Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Pfizer Inc.
    • PharmaChoice Canada Inc
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited.
    • Valneva SE
Product Code: SR112024A4973

The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032. The increasing public awareness of cholera prevention, robust government initiatives and international collaboration, continual advancements in vaccine technology, the surge in travel and trade, ongoing research and development activities, and the emphasis on global health are some of the factors fueling the market growth.

Cholera vaccines are medical interventions designed to provide protection against cholera, a bacterial infection that causes diarrhea and can lead to dehydration and even death. They are developed using a combination of inactivated or attenuated Vibrio cholerae bacteria, the causative agent of cholera. The process involves growing large quantities of the bacteria, rendering them non-virulent, and then formulating them into vaccines. The advantages of cholera vaccines are significant, such as they offer a proactive approach to preventing cholera outbreaks, particularly in regions with inadequate sanitation and water supplies. By bolstering the immune system's ability to recognize and fight the cholera bacteria, these vaccines can reduce the severity and duration of the illness. Moreover, they contribute to reducing the transmission of cholera within communities and across borders. Two main types of cholera vaccines include oral and injectable.

The global cholera vaccines market is influenced by the increasing awareness about cholera prevention and the importance of vaccination, especially in regions prone to outbreaks. Additionally, government initiatives and international organizations' efforts to control cholera's spread through vaccination campaigns play a pivotal role in market expansion. Moreover, advancements in vaccine technology, resulting in the development of more efficient and cost-effective vaccines, bolster market growth. Furthermore, the rising frequency of travel and international trade fosters the need for cholera vaccination, as travelers can potentially carry the disease across borders, which, in turn, is supporting the market growth. Besides this, ongoing research and development (R&D) activities aimed at enhancing vaccine efficacy and safety are contributing to the market growth.

Cholera Vaccines Market Trends/Drivers:

Increasing awareness and cholera prevention

The global cholera vaccines market experiences a significant impetus from the increasing awareness surrounding cholera prevention and the crucial role of vaccination. As communities become more informed about the devastating impact of cholera outbreaks, the demand for effective preventive measures, including vaccination, rises. This heightened awareness is often driven by public health campaigns, educational initiatives, and media coverage that highlight the consequences of cholera and the importance of vaccination in curbing its spread. This driver not only stimulates individual and community-level interest in vaccination but also encourages governments, healthcare organizations, and international bodies to allocate resources towards vaccination campaigns, propelling market growth.

Government initiatives and international efforts

Government initiatives and collaborative efforts by international organizations contribute significantly to the expansion of the global cholera vaccines market. Governments of cholera-prone regions recognize the socio-economic burden posed by cholera and prioritize vaccination programs as a crucial preventive strategy. Moreover, international organizations like the World Health Organization (WHO) and UNICEF engage in partnerships with governments, providing technical expertise, funding, and vaccine supply to support vaccination campaigns. This coordinated approach not only ensures vaccine accessibility in resource-constrained regions but also fosters a conducive environment for market growth by creating a steady demand for cholera vaccines.

Advancements in vaccine technology

Advancements in vaccine technology play a pivotal role in propelling the global cholera vaccines market forward. As research and development efforts focus on improving vaccine efficacy, safety, and production processes, newer and more effective cholera vaccines are introduced to the market. These advancements enable the creation of vaccines that offer longer-lasting protection, require fewer doses, and are suitable for a wider range of age groups. Additionally, innovations in vaccine delivery mechanisms, such as oral vaccines, contribute to increased vaccine acceptance and ease of administration, particularly in areas with limited healthcare infrastructure. The continuous evolution of vaccine technology not only enhances the overall effectiveness of cholera vaccines but also fuels market growth by providing healthcare providers and communities with better tools for disease prevention.

Cholera Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit

Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes whole cell V. cholerae O1 with recombinant B-subunit and killed oral O1 and O139. According to the report, whole cell V. cholerae O1 with recombinant B-subunit represented the largest segment.

The whole cell V. cholerae O1 with recombinant B-subunit segment is propelled by the comprehensive protection offered by whole-cell vaccines against cholera caused by V. cholerae O1. The inclusion of recombinant B-subunit enhances immunogenicity, bolstering the vaccine's efficacy in inducing protective immune responses. Additionally, the rising global awareness about cholera's impact on public health underscores the importance of advanced vaccines. Moreover, governmental initiatives and collaborations with international health organizations amplify the distribution and administration of these vaccines, especially in endemic regions. In line with this, ongoing research and development efforts continually refine vaccine formulations, ensuring optimal safety and effectiveness. Apart from this, the evolving landscape of international travel and trade heightens the demand for robust preventive measures, boosting the adoption of this segment.

Breakup by Product:

Dukoral

Shanchol

Vaxchora

Euvichol and Euvichol-Plus

Others

Dukoral dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes dukoral, shanchol, vaxchora, euvichol and euvichol-plus, and others. According to the report, dukoral represented the largest segment.

The dukoral segment is propelled by the surging awareness regarding the unique formulation of the product, encompassing both cholera and ETEC (enterotoxigenic Escherichia coli) antigens. Additionally, its established reputation for safety and efficacy, backed by rigorous clinical trials, instills confidence among healthcare professionals and recipients alike, boosting its adoption. Moreover, the expanding travel and tourism sector drives demand for dukoral, as it addresses the risk of cholera and ETEC infections associated with global mobility. Furthermore, its oral administration aligns with the preference for non-invasive vaccination methods, especially in regions with limited healthcare infrastructure. In line with this, ongoing research to refine dukoral's formulation and increase accessibility in underserved areas underscores its significance, solidifying its position as a driver in the market's growth trajectory.

Breakup by End User:

Hospitals and Clinics

Research and Academic Laboratories

Others

Hospitals and clinics dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, research and academic laboratories, and others. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment dominates the market due to the increasing demand for quality healthcare services and medical interventions. Hospitals and clinics serve as primary access points for medical care, catering to a wide range of medical needs from routine check-ups to specialized treatments. Additionally, advancements in medical technology and treatments drive the need for modern and well-equipped healthcare facilities. Patients seek out hospitals and clinics that offer cutting-edge diagnostic and treatment options, thus encouraging the growth of this segment. Moreover, the growing aging population contributes significantly to the demand for healthcare services. As elderly individuals require more frequent medical attention, hospitals and clinics play a crucial role in providing geriatric care. Furthermore, the rise in chronic diseases necessitates ongoing medical care and management, prompting a greater reliance on hospitals and clinics for continuous patient support.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North American cholera vaccines market is stimulated by a solid healthcare framework and an emphasis on disease prevention, with stringent public health policies and high awareness increasing demand. International travel and trade further necessitate vaccination. In Asia Pacific, rising cholera outbreaks, lack of sanitation, government efforts, population density, and tourism focus attention on vaccination. Europe's market is propelled by strong healthcare systems and proactive disease surveillance, while travel and trade accentuate the requirement for vaccination. Latin America's growth is due to uneven access to sanitation and government campaigns. In the Middle East and Africa, erratic sanitation infrastructure and recurring cholera outbreaks necessitate vaccines, with governmental and international efforts addressing waterborne diseases.

Competitive Landscape:

The competitive landscape within the market for cholera vaccine is characterized by a dynamic interplay of various factors that shape the positioning of key players. Market participants engage in a multitude of strategies to gain a competitive edge, including product innovation, strategic collaborations, geographical expansion, and mergers and acquisitions. The quest to capture larger market shares and establish brand prominence drives companies to invest in research and development, aiming to offer novel solutions that cater to evolving consumer needs. Furthermore, the emphasis on customer-centric approaches and effective marketing strategies is pivotal in differentiating brands in a crowded marketplace. Regulatory compliance and adherence to industry standards also contribute to the competitive dynamics. The competitive landscape is ever evolving, with players continuously adapting to market trends, customer preferences, and technological advancements to maintain their relevance and sustain growth in this competitive arena.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Astellas Pharma Inc.

Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)

Emergent BioSolutions Inc.

Eubiologics Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Pfizer Inc.

PharmaChoice Canada Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Valneva SE

Recent Developments:

In June 2022, Sanofi unveiled the initiation of its first Digital Accelerator, a significant step that aligns with its aspiration to evolve into a top-tier digital healthcare company.

Key Questions Answered in This Report

  • 1. What was the size of the global cholera vaccines market in 2023?
  • 2. What is the expected growth rate of the global cholera vaccines market during 2024-2032?
  • 3. What are the key factors driving the global cholera vaccines market?
  • 4. What has been the impact of COVID-19 on the global cholera vaccines market?
  • 5. What is the breakup of the global cholera vaccines market based on the vaccine type?
  • 6. What is the breakup of the global cholera vaccines market based on the product?
  • 7. What is the breakup of the global cholera vaccines market based on the end user?
  • 8. What are the key regions in the global cholera vaccines market?
  • 9. Who are the key players/companies in the global cholera vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Killed Oral O1 and O139
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Dukoral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shanchol
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Vaxchora
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Euvichol and Euvichol-Plus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research and Academic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Emergent BioSolutions Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eubiologics Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 PharmaChoice Canada Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Valneva SE
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cholera Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cholera Vaccines Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Cholera Vaccines Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Cholera Vaccines Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Cholera Vaccines Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Cholera Vaccines Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cholera Vaccines (Killed Oral O1 and O139) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cholera Vaccines (Killed Oral O1 and O139) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cholera Vaccines (Dukoral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cholera Vaccines (Dukoral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cholera Vaccines (Shanchol) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cholera Vaccines (Shanchol) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cholera Vaccines (Vaxchora) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cholera Vaccines (Vaxchora) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cholera Vaccines (Other Product) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cholera Vaccines (Other Product) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cholera Vaccines (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cholera Vaccines (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cholera Vaccines (Research and Academic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cholera Vaccines (Research and Academic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cholera Vaccines (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cholera Vaccines (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Cholera Vaccines Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Cholera Vaccines Industry: SWOT Analysis
  • Figure 78: Global: Cholera Vaccines Industry: Value Chain Analysis
  • Figure 79: Global: Cholera Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cholera Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cholera Vaccines Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Cholera Vaccines Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Cholera Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Cholera Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cholera Vaccines Market: Competitive Structure
  • Table 7: Global: Cholera Vaccines Market: Key Players